TABLE 2
FROM:
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole
D Saltzstein, P Sieber, T Morris and J Gallo
BACK TO ARTICLETable 2. Changes in serum levels of sex hormones in healthy volunteers (n=7) receiving bicalutamide 150 mg plus tamoxifen 20 mg (both from days 1 to 42) in the pilot study
| Time (days) | |||||
|---|---|---|---|---|---|
| 1 | 8 | 22 | 43 | 84−90 (follow-up) | |
| Free testosterone | |||||
| Geometric mean (CV) (nmol/l) | 0.045 (11.970) | 0.059 (18.628) | 0.077 (34.582) | 0.063 (34.303) | 0.056 (22.686) |
| % change from baseline | — | 31 | 71 | 40 | 24 |
| Total testosterone | |||||
| Mean (s.d.) (nmol/l) | 14.82 (2.11) | 21.38 (3.90) | 22.92 (4.42) | 22.50 (5.19) | 24.19 (6.49) |
| % change from baseline | — | 44 | 55 | 52 | 63 |
| Dihydrotestosterone | |||||
| Mean (s.d.) (pg/ml) | 666.3 (177.2) | 830.7 (169.8) | 973.4 (207.5) | 785.7 (224.3) | 875.6 (308.7) |
| % change from baseline | — | 25 | 46 | 18 | 31 |
| Luteinizing hormone | |||||
| Mean (s.d.) (IU/l) | 3.34 (1.61) | 8.21 (3.38) | 12.56 (6.84) | 13.34 (8.04) | 6.56 (2.52) |
| % change from baseline | — | 146 | 276 | 299 | 96 |
| Sex hormone binding globulin | |||||
| Mean (s.d.) (pmol/ml) | 0.083 (0.011) | 0.093 (0.020) | 0.083 (0.017) | 0.067 (0.016) | 0.068 (0.019) |
| % change from baseline | — | 12 | 0 | -20 | -18 |
| Prolactin | |||||
| Mean (s.d.) (IU/l) | 5.04 (2.30) | 5.63 (2.84) | 4.80 (3.46) | 5.53 (3.11) | 6.11 (2.86) |
| % change from baseline | — | 12 | -5 | 10 | 21 |
| Follicle-stimulating hormone | |||||
| Mean (s.d.) (IU/l) | 5.87 (4.23) | 8.71 (6.2) | 8.34 (6.63) | 9.33 (7.38) | 7.04 (5.23) |
| % change from baseline | — | 48 | 42 | 59 | 20 |
| Estradiol | |||||
| Mean (s.d.) (pmol/l) | 95.71 (24.30) | 105.00 (25.36) | 133.57 (26.39) | 131.57 (40.32) | 135.29 (34.45) |
| % change from baseline | — | 10 | 40 | 37 | 41 |
CV, coefficient of variation; s.d., standard deviation.
